Literature DB >> 24021761

The controversial role of chemoradiation for patients with locally advanced pancreatic cancer.

Jason E Faris1, Jennifer Y Wo.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24021761      PMCID： PMC3780645          DOI： 10.1634/theoncologist.2013-0270

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  20 in total

1.  Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.

Authors:  Ross A Abrams; Kathryn A Winter; William F Regine; Howard Safran; John P Hoffman; Robert Lustig; Andre A Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-01       Impact factor: 7.038

Review 2.  Treatment of locally advanced pancreatic cancer: the role of radiation therapy.

Authors:  Kimberly Johung; Muhammad Wasif Saif; Bryan W Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-09       Impact factor: 7.038

3.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Authors:  Jason E Faris; Lawrence S Blaszkowsky; Shaunagh McDermott; Alexander R Guimaraes; Jackie Szymonifka; Mai Anh Huynh; Cristina R Ferrone; Jennifer A Wargo; Jill N Allen; Lauren E Dias; Eunice L Kwak; Keith D Lillemoe; Sarah P Thayer; Janet E Murphy; Andrew X Zhu; Dushyant V Sahani; Jennifer Y Wo; Jeffrey W Clark; Carlos Fernandez-del Castillo; David P Ryan; Theodore S Hong
Journal:  Oncologist       Date:  2013-05-08

4.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

5.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Authors:  Christopher H Crane; Gauri R Varadhachary; John S Yordy; Gregg A Staerkel; Milind M Javle; Howard Safran; Waqar Haque; Bridgett D Hobbs; Sunil Krishnan; Jason B Fleming; Prajnan Das; Jeffrey E Lee; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

6.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Authors:  Daniel D Von Hoff; Ramesh K Ramanathan; Mitesh J Borad; Daniel A Laheru; Lon S Smith; Tina E Wood; Ronald L Korn; Neil Desai; Vuong Trieu; Jose L Iglesias; Hui Zhang; Patrick Soon-Shiong; Tao Shi; N V Rajeshkumar; Anirban Maitra; Manuel Hidalgo
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

7.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

Authors:  Patrick J Loehrer; Yang Feng; Higinia Cardenes; Lynne Wagner; Joanna M Brell; David Cella; Patrick Flynn; Ramesh K Ramanathan; Christopher H Crane; Steven R Alberts; Al B Benson
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

8.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

Authors:  B Chauffert; F Mornex; F Bonnetain; P Rougier; C Mariette; O Bouché; J F Bosset; T Aparicio; L Mineur; A Azzedine; P Hammel; J Butel; N Stremsdoerfer; P Maingon; L Bedenne
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976

9.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.

Authors:  Sunil Krishnan; Vishal Rana; Nora A Janjan; Gauri R Varadhachary; James L Abbruzzese; Prajnan Das; Marc E Delclos; Morris S Gould; Douglas B Evans; Robert A Wolff; Christopher H Crane
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

10.  A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

Authors:  Peter J Hosein; Jessica Macintyre; Carolina Kawamura; Jennifer Cudris Maldonado; Vinicius Ernani; Arturo Loaiza-Bonilla; Govindarajan Narayanan; Afonso Ribeiro; Lorraine Portelance; Jaime R Merchan; Joe U Levi; Caio M Rocha-Lima
Journal:  BMC Cancer       Date:  2012-05-29       Impact factor: 4.430
View more
  1 in total

Review 1.  Advances in chemotherapy for pancreatic cancer.

Authors:  Bhawna Sirohi; Ashish Singh; Shaheenah Dawood; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2015-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.